Desloratadine Patent Expiration
Desloratadine is used for treating symptoms of allergic rhinitis and chronic idiopathic urticaria. It was first introduced by Organon Llc A Sub Of Organon And Co
Desloratadine Patents
Given below is the list of patents protecting Desloratadine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Clarinex |
US7618649 (Pediatric) | Extended release oral dosage composition |
Jun 19, 2021
(Expired) | Organon |
| Clarinex | US7618649 | Extended release oral dosage composition |
Dec 19, 2020
(Expired) | Organon |
| Clarinex |
US6100274 (Pediatric) | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan 07, 2020
(Expired) | Organon |
| Clarinex |
US7405223 (Pediatric) | Treating allergic and inflammatory conditions |
Jan 07, 2020
(Expired) | Organon |
| Clarinex | US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul 07, 2019
(Expired) | Organon |
| Clarinex | US7405223 | Treating allergic and inflammatory conditions |
Jul 07, 2019
(Expired) | Organon |
| Clarinex |
US6514520 (Pediatric) | Stabilized antihistamine syrup |
Dec 01, 2018
(Expired) | Organon Llc |
| Clarinex | US6514520 | Stabilized antihistamine syrup |
Jun 01, 2018
(Expired) | Organon Llc |
| Clarinex |
US5607697 (Pediatric) | Taste masking microparticles for oral dosage forms |
Dec 07, 2015
(Expired) | Organon |
| Clarinex |
US7211582 (Pediatric) | Methods for treating urticaria using descarboethoxyloratadine |
Jun 30, 2015
(Expired) | Organon |
| Clarinex |
US7211582 (Pediatric) | Methods for treating urticaria using descarboethoxyloratadine |
Jun 30, 2015
(Expired) | Organon Llc |
| Clarinex |
US7214683 (Pediatric) | Compositions of descarboethoxyloratadine |
Jun 30, 2015
(Expired) | Organon |
| Clarinex |
US7214683 (Pediatric) | Compositions of descarboethoxyloratadine |
Jun 30, 2015
(Expired) | Organon Llc |
| Clarinex |
US7214684 (Pediatric) | Methods for the treatment of allergic rhinitis |
Jun 30, 2015
(Expired) | Organon |
| Clarinex |
US7214684 (Pediatric) | Methods for the treatment of allergic rhinitis |
Jun 30, 2015
(Expired) | Organon Llc |
| Clarinex | US5607697 | Taste masking microparticles for oral dosage forms |
Jun 07, 2015
(Expired) | Organon |
| Clarinex | US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
Dec 30, 2014
(Expired) | Organon |
| Clarinex | US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
Dec 30, 2014
(Expired) | Organon Llc |
| Clarinex | US7214683 | Compositions of descarboethoxyloratadine |
Dec 30, 2014
(Expired) | Organon |
| Clarinex | US7214683 | Compositions of descarboethoxyloratadine |
Dec 30, 2014
(Expired) | Organon Llc |
| Clarinex | US7214684 | Methods for the treatment of allergic rhinitis |
Dec 30, 2014
(Expired) | Organon |
| Clarinex | US7214684 | Methods for the treatment of allergic rhinitis |
Dec 30, 2014
(Expired) | Organon Llc |
Desloratadine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Desloratadine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
